Recently, Neutroplast concluded the acquisition of BeyonDevices, a technology transfer company which has developed a promising portfolio of breakthrough technology in the Pharmaceutical Primary Packaging, Medical Technology and Devices industries.
The innovative processes at BeyonDevices, which have made it a renowned product development specialist, have their most visible results in the EasyGyn medical device for women?s health and the GLORIA smart-packaging project, which aims to bring the Internet of Things to the use of pharmaceutical drugs on our everyday life. Now, these products will be available for fully proprietary scale-up by Neutroplast, but there is more to this acquisition than simply extending our product range.
A step further for Innovation
BeyonDevices was originally a spin-off of Neutroplast, and the integration of new technologies will advance our current product range with exciting new products, but the synergies generated by the deal go further than product development. In fact, BeyonDevices has created significant momentum in the European R&D landscape, partnering in multiple cooperation projects as a technology developer and consultant, which means that, by bringing BeyonDevices back to its core business, Neutroplast?s is integrating not only new technologies but specifically strengthening its Innovation and Development capacities, in markets which are its core business.
In sum, today the future of R&D looks bright at Neutroplast, and having BeyonDevices in our fold has only made it shine brighter, as Neutroplast?s next developments will be, now more than ever, a source of Pharmaceutical Packaging Industry breakthroughs.